[{"address1": "200-3650 Gilmore Way", "city": "Burnaby", "state": "BC", "zip": "V5G 4W8", "country": "Canada", "phone": "604 484 3300", "fax": "604 484 3450", "website": "https://www.xenon-pharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders in Canada. Its product candidates include Azetukalner, a selective Kv7 potassium channel opener in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.", "fullTimeEmployees": 316, "companyOfficers": [{"maxAge": 1, "name": "Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.", "age": 48, "title": "President, CEO, Principal Accounting Officer & Director", "yearBorn": 1976, "fiscalYear": 2024, "totalPay": 1184288, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Andrea  DiFabio J.D.", "age": 56, "title": "Chief Legal Officer & Corporate Secretary", "yearBorn": 1968, "fiscalYear": 2024, "totalPay": 682252, "exercisedValue": 0, "unexercisedValue": 436894}, {"maxAge": 1, "name": "Dr. Christopher John Kenney M.D.", "age": 53, "title": "Chief Medical Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 774702, "exercisedValue": 0, "unexercisedValue": 4053263}, {"maxAge": 1, "name": "Mr. Thomas Patrick Kelly J.D.", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Matthew D. Ronsheim Ph.D.", "age": 52, "title": "Chief Operating Officer", "yearBorn": 1972, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Shelley  McClCoskey B.A.", "age": 64, "title": "Executive Vice President of Human Resources", "yearBorn": 1960, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Robin P. Sherrington Ph.D.", "age": 63, "title": "Executive Vice President of Strategy & Innovation", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 587028, "exercisedValue": 0, "unexercisedValue": 9907717}, {"maxAge": 1, "name": "Dr. James R. Empfield Ph.D.", "age": 63, "title": "Executive Vice President of Drug Discovery", "yearBorn": 1961, "fiscalYear": 2024, "totalPay": 323428, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Darren S. Cline M.B.A.", "age": 60, "title": "Chief Commercial Officer and Member of Executive Team", "yearBorn": 1964, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 9, "boardRisk": 2, "compensationRisk": 8, "shareHolderRightsRisk": 3, "overallRisk": 5, "governanceEpochDate": 1761955200, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 40.04, "open": 39.86, "dayLow": 39.86, "dayHigh": 41.18, "regularMarketPreviousClose": 40.04, "regularMarketOpen": 39.86, "regularMarketDayLow": 39.86, "regularMarketDayHigh": 41.18, "payoutRatio": 0.0, "beta": 1.034, "forwardPE": -11.449438, "volume": 1039281, "regularMarketVolume": 1039281, "averageVolume": 756796, "averageVolume10days": 829510, "averageDailyVolume10Day": 829510, "bid": 40.71, "ask": 40.84, "bidSize": 8, "askSize": 2, "marketCap": 3149729280, "fiftyTwoWeekLow": 26.74, "fiftyTwoWeekHigh": 44.23, "allTimeHigh": 50.99, "allTimeLow": 2.1, "priceToSalesTrailing12Months": 419.9639, "fiftyDayAverage": 39.4698, "twoHundredDayAverage": 35.693974, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 2695788288, "profitMargins": 0.0, "floatShares": 71764524, "sharesOutstanding": 77275005, "sharesShort": 5785686, "sharesShortPriorMonth": 7705812, "sharesShortPreviousMonthDate": 1759190400, "dateShortInterest": 1761868800, "sharesPercentSharesOut": 0.0749, "heldPercentInsiders": 0.0014300001, "heldPercentInstitutions": 1.1294999, "shortRatio": 7.19, "shortPercentOfFloat": 0.083500005, "impliedSharesOutstanding": 77275005, "bookValue": 7.255, "priceToBook": 5.618194, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -306334016, "trailingEps": -3.89, "forwardEps": -3.56, "enterpriseToRevenue": 359.438, "enterpriseToEbitda": -7.971, "52WeekChange": 0.06395197, "SandP52WeekChange": 0.14261019, "quoteType": "EQUITY", "currentPrice": 40.76, "targetHighPrice": 65.0, "targetLowPrice": 43.0, "targetMeanPrice": 54.98105, "targetMedianPrice": 55.0, "recommendationMean": 1.2, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 19, "totalCash": 462268000, "totalCashPerShare": 5.982, "ebitda": -338182016, "totalDebt": 8327000, "quickRatio": 12.08, "currentRatio": 12.525, "totalRevenue": 7500000, "debtToEquity": 1.488, "revenuePerShare": 0.095, "returnOnAssets": -0.29505, "returnOnEquity": -0.45138, "grossProfits": -265211008, "freeCashflow": -162175504, "operatingCashflow": -252022000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": -45.43733, "financialCurrency": "USD", "symbol": "XENE", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "longName": "Xenon Pharmaceuticals Inc.", "epsTrailingTwelveMonths": -3.89, "epsForward": -3.56, "epsCurrentYear": -4.24393, "priceEpsCurrentYear": -9.604305, "fiftyDayAverageChange": 1.2901993, "fiftyDayAverageChangePercent": 0.032688268, "twoHundredDayAverageChange": 5.066025, "twoHundredDayAverageChangePercent": 0.14192942, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.2 - Strong Buy", "cryptoTradeable": false, "corporateActions": [], "postMarketTime": 1763165085, "regularMarketTime": 1763154000, "exchange": "NGM", "messageBoardId": "finmb_565718", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EST", "gmtOffSetMilliseconds": -18000000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 1.7982, "regularMarketPrice": 40.76, "marketState": "CLOSED", "shortName": "Xenon Pharmaceuticals Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1415197800000, "postMarketChangePercent": 4.0235605, "postMarketPrice": 42.4, "postMarketChange": 1.6400032, "regularMarketChange": 0.719997, "regularMarketDayRange": "39.86 - 41.18", "fullExchangeName": "NasdaqGM", "averageDailyVolume3Month": 756796, "fiftyTwoWeekLowChange": 14.019999, "fiftyTwoWeekLowChangePercent": 0.5243081, "fiftyTwoWeekRange": "26.74 - 44.23", "fiftyTwoWeekHighChange": -3.4700012, "fiftyTwoWeekHighChangePercent": -0.07845356, "fiftyTwoWeekChangePercent": 6.395197, "earningsTimestamp": 1762203600, "earningsTimestampStart": 1762203600, "earningsTimestampEnd": 1762203600, "earningsCallTimestampStart": 1762205400, "earningsCallTimestampEnd": 1762205400, "isEarningsDateEstimate": false, "displayName": "Xenon Pharmaceuticals", "trailingPegRatio": null, "__fetch_time": "2025-11-15"}]